Reid, Tony <br/><br/>
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.  [electronic resource] 

 -  The Lancet. Oncology  Sep 2015 
 - 1133-1142 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)00089-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Azetidines--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions--pathology<br/>Epigenesis, Genetic--drug effects<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Nitro Compounds--administration & dosage<br/>Prognosis<br/>Treatment Outcome